GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study

What happened

GSK and Hansoh Pharmaceutical are developing an experimental bone cancer drug called ris-rez. In a late-stage study in China of 122 patients with relapsed refractory osteosarcoma, patients on ris-rez lived a median of 5.5 months without disease worsening, compared with 1.4 months for those on chemotherapy.

Confirmed

Global impact / market context

The trial result is central to GSK's plan to rebuild its cancer business, a decade after leaving it. If approved, ris-rez could give patients with hard-to-treat bone cancer a new option and give GSK a foothold in oncology that may support future revenue.

Analyst inference

GSK licensed ris-rez from Hansoh, a Hong Kong-listed Chinese drugmaker, and is accelerating development across several cancers. Positive late-stage data from China are a step toward broader use, but the drug still needs regulatory review before it can reach patients outside the trial.

Analyst inference

What to watch

1. The trial tested ris-rez in 122 patients aged 12 and older with relapsed refractory osteosarcoma, which means cancer that has come back and stopped responding to more than two prior treatments. Confirmed
2. GSK and Hansoh could seek approval from health regulators in China and other markets, using the late-stage data to support a filing, though no filing or timeline is confirmed in the article. Proposed
3. Investors may watch for further late-stage results in other cancers, because GSK is accelerating ris-rez development and broader success would strengthen its rebuilt cancer business and potential revenue. Analyst inference

Evidence

• Original source link unavailable